NCT02257619 2026-04-21
Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer
Incyte Corporation
Phase 2 Terminated
Clinical Trials
5 trialsNCT05757219 2026-03-31
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT04509700 2025-12-10
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
Incyte Corporation
Phase 2 Active not recruiting
NCT04629508 2025-09-02
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
Incyte Corporation
Phase 2 Completed
NCT05364762 2025-05-30
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants
City of Hope Medical Center
Phase 2 Active not recruiting